KIT and melanoma: A pharmacodynamic study during a phase II clinical trial with nilotinib in KIT-altered melanoma [16] showed a trend towards a reduction of growth factor expression in good responders compared to poor responders suggesting a link between growth factors and resistance to KIT inhibitors (Figure 2).